AtriCure, Inc. (ATRC) News
Filter ATRC News Items
ATRC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ATRC News From Around the Web
Below are the latest news stories about ATRICURE INC that investors may wish to consider to help them evaluate ATRC as an investment opportunity.
Wall Street Analysts Predict a 36.34% Upside in AtriCure (ATRC): Here's What You Should KnowThe consensus price target hints at a 36.3% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
AtriCure to Participate in the Piper Sandler 35th Annual Healthcare ConferenceMASON, Ohio, November 15, 2023--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Piper Sandler 35th Annual Healthcare Conference. |
AtriCure Releases 2023 ESG ReportMASON, Ohio, November 14, 2023--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced that the company has published its 2023 Environmental, Social and Governance (ESG) Report highlighting the company’s corporate responsibility and sustainability initiatives. |
All You Need to Know About AtriCure (ATRC) Rating Upgrade to BuyAtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
AtriCure, Inc. (NASDAQ:ATRC) Q3 2023 Earnings Call TranscriptAtriCure, Inc. (NASDAQ:ATRC) Q3 2023 Earnings Call Transcript November 1, 2023 AtriCure, Inc. beats earnings expectations. Reported EPS is $-0.2, expectations were $-0.3. Operator: Good afternoon, and welcome to AtriCure’s Third Quarter 2023 Earnings Conference Call. At this time, all participants are in listen-only mode. We will be facilitating a question-and-answer session towards the end […] |
Q3 2023 AtriCure Inc Earnings CallQ3 2023 AtriCure Inc Earnings Call |
AtriCure Inc (ATRC) Reports Q3 2023 Earnings: 18.1% YoY Revenue GrowthImproved Net Loss and Positive Adjusted EBITDA Highlight AtriCure's Financial Performance |
AtriCure (ATRC) Reports Q3 Earnings: What Key Metrics Have to SayAlthough the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
AtriCure Reports Third Quarter 2023 Financial ResultsMASON, Ohio, November 01, 2023--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2023 financial results. |
AtriCure to Participate in the Stifel 2023 Healthcare ConferenceMASON, Ohio, October 31, 2023--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Stifel 2023 Healthcare Conference. |